sars-cov-2 fusion protein vaccine
Vaccineexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Aug 5, 2021 (NCT05239832)
Timeline
Indications
Studied for
Mechanism of action
- Spike glycoproteinImmunity, active
Spike glycoprotein immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05273528 | Phase 2 | Jan 11, 2022 | Livzon Pharmaceutical Group Inc. |
| NCT05238649 | Phase 2 | Nov 10, 2021 | Livzon Pharmaceutical Group Inc., Zhuhai People's Hospital Medical Group |
| NCT05096832 | Phase 3 | Oct 31, 2021 | Livzon Pharmaceutical Group Inc. |
| NCT05125874 | N/A | Sep 30, 2021 | Livzon Pharmaceutical Group Inc., Zhuhai People's Hospital Medical Group |
| NCT05096845 | Phase 3 | Aug 25, 2021 | Livzon Pharmaceutical Group Inc. |
| NCT05050474 | Phase 1 | Aug 7, 2021 | Government of China, Livzon Pharmaceutical Group Inc. |
| NCT05239832 | Phase 2 | Aug 5, 2021 | Livzon Pharmaceutical Group Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Livzon Pharmaceutical Group Inc. | For profit | 7 | 7 | 4 | 2021 |
| Zhuhai People's Hospital Medical Group | Academic/Hospital | 2 | 0 | 2 | 2021 |
| Government of China | Government | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1